Anavex Life Sciences Corp (AVXL)

[falconer66a]

MOA Validations

I contend that in addition to the side effects differentiation of Anavex over Acadia, a powerful driver of the Anavex drug, first for Rett, then for the other CNS indications being targeted (being tested in clinical trials) will be blarcamesine's mechanism of actions (MOA).

If the Acadia drug gains approval for the treatment of Rett syndrome, will that approval tend to validate any other Acadia drugs or indications? Is the MOA of the Acadia drug applicable by extension to any other diseases? I see no evidence of such.

But when blarcamesine (Anavex 2-73) gains FDA approval for Rett therapy, its unique MOA (propitious activation of the sigma-1 receptor protein) will be recognized and clinically demonstrated. With that, it will be understood how it then, by the same MOA, can be therapeutic for other CNS diseases.

For both drugs, validation of the MOA will be important. For Anavex, it will validate potential therapies for other CNS diseases. Two of those are in clinical trial, Parkinson's disease dementia, and Alzheimer's. With the safety and therapeutic success against Rett syndrome, clinical successes demonstrated in the other two trials will be ever more sound. Approval for them should be forthcoming.